UGT1A1 and Thrombocytopenia: A phase I trial investigated the effects of UGT1A1 polymorphisms on the pharmacokinetics and toxicities (fatigue, nausea, vomiting, lethargy, neutropenia, and thrombocytopenia) of 48-hour continuous infusion belinostat.